Hereditary cancer risk assessment in a pediatric oncology follow‐up clinic
- 17 August 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 58 (1), 85-89
- https://doi.org/10.1002/pbc.23283
Abstract
Background Pediatric cancer survivors are at risk for multiple late effects including second malignancies, some a direct consequence of genetic susceptibility. Appropriate surveillance and management for the survivor and at-risk family members can often be established if the genetic predisposition is recognized and/or diagnosed. Numerous published guidelines outline which adult cancer patients and survivors should be referred for hereditary cancer risk assessment. In the pediatric oncology setting, minimal guidance exists for healthcare providers to determine which patients and families to refer for genetic evaluation. Procedure The aim of this project was to determine what percentage of childhood cancer survivors are appropriate for further evaluation in a hereditary cancer program or genetics clinic and characterize indications for referral. Participants included pediatric cancer survivors seen for follow-up in a large cancer survivor center. Medical and family histories were obtained and reviewed by a certified genetic counselor at the survivor's annual visit. Eligibility for genetics referral was determined based on personal/family medical history and published literature. Results Of 370 survivors of childhood cancer, 109 (29%) were considered eligible for genetics follow-up or referral. Family history of cancer is the most prevalent reason identified for eligibility for further genetics evaluation (61%) followed by tumor type (18%), medical history (16%), and family history of another condition (6%). Conclusions This project provides evidence that inclusion of genetic evaluation is feasible and relevant in the care of childhood cancer survivors. Further study is warranted to determine optimal timing and clinical utility of this multidisciplinary and family-centered approach. Pediatr Blood Cancer 2012; 58: 85–89.This publication has 16 references indexed in Scilit:
- Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline MutationsJournal of Clinical Oncology, 2009
- Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-upJNCI Journal of the National Cancer Institute, 2008
- Genetic testing and tumor surveillance for children with cancer predisposition syndromesCurrent Opinion in Pediatrics, 2008
- Hereditary cancer predisposition in children: Genetic basis and clinical implicationsInternational Journal of Cancer, 2006
- Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?Pediatric Blood & Cancer, 2005
- High incidence of malformation syndromes in a series of 1,073 children with cancerAmerican Journal of Medical Genetics Part A, 2005
- Inherited cancer in children: practical/ethical problems and challengesEuropean Journal of Cancer, 2004
- Referral for cancer genetics consultation: a review and compilation of risk assessment criteriaJournal of Medical Genetics, 2004
- Cancer Incidence After RetinoblastomaJAMA, 1997
- Genetic counseling of the cancer survivorSeminars in Oncology Nursing, 1989